Eli Lilly — Oct 30, 2025 release

8 The following table summarizes the company's updated 2025 financial guidance: Prior Updated (1) (2) (3) Revenue $60.0 to $62.0 billion $63.0 to $63.5 billion Performance Margin (4) (reported) 42.0% to 43.5% 43.5% to 44.5% (non-GAAP) 43.0% to 44.5% 45.0% to 46.0% Other Income/(Expense) (reported) ($750) to ($650) million ($700) to ($600) million Other Income/(Expense) (non-GAAP) ($700) to ($600) million Unchanged Tax Rate (reported) Approx. 19% Unchanged Tax Rate (non-GAAP) Approx. 17% Unchanged Earnings per Share (reported) $20.85 to $22.10 $21.80 to $22.50 Earnings per Share (non-GAAP) $21.75 to $23.00 $23.00 to $23.70 (1) Non-GAAP guidance reflects adjustments presented in the earnings per share reconciliation table above. (2) Guidance includes acquired IPR&D charges through Q3 2025 of $2.38 billion or $2.57 on a per share basis. Guidance does not include acquired IPR&D either incurred, or expected to be incurred, after Q3 2025. (3) This guidance is based on the existing tariff and trade environment as of October 30, 2025, and does not reflect any policy shifts, including pharmaceutical sector tariffs, that could impact business. (4) The Company defines performance margin as gross margin less R&D, Marketing, Selling, and Administrative, and Asset Impairment, Restructuring and Other Charges divided by Revenue. 9 Webcast of Conference Call As previously announced, investors and the general public can access a live webcast of the Q3 2025 financial results conference call through a link on Lilly's website at investor.lilly.com/webcasts-and-presentations. The conference call will begin at 10